Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.mankindpharma.com | |
Market Cap | 95,940.93 Cr. | |
Enterprise Value(EV) | 95,511.62 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 43.11 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 55.55 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.74 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 221.77 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 10.80 | Calculated using Price: 2,395.00 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 40.06 Cr. | 400,588,440 Shares |
FaceValue | 1 | |
About Mankind Pharma Ltd. | ||
The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. |
1 Day |
|
-1.23% |
1 Week |
|
-1.11% |
1 Month |
|
+7.01% |
3 Month |
|
+16.68% |
6 Month |
|
+37.00% |
1 Year |
|
|
2 Year |
|
|
5 Year |
|
|
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 21.61 | 25.06 | 23.76 | 23.13 | 21.41 | 33.48 | 31.51 | 26.72 | 19.27 | |
Return on Capital Employed (%) | 30.32 | 36.47 | 34.98 | 32.75 | 28.8 | 43.57 | 39.97 | 33.96 | 23.49 | |
Return on Assets (%) | 17.54 | 20.08 | 18.69 | 16.58 | 14.46 | 23.19 | 22.79 | 18.83 | 13.94 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 2,055 | 2,257 | 2,927 | 2,881 | 2,823 | 3,485 | 4,722 | 6,155 | 7,435 | 8,428 | |
Non Curr. Liab. | 28 | 34 | 53 | 49 | 78 | 103 | 107 | 169 | 199 | 236 | |
Curr. Liab. | 433 | 528 | 663 | 1,296 | 1,024 | 1,251 | 1,353 | 2,623 | 1,863 | 2,128 | |
Minority Int. | 16 | 29 | 98 | 134 | 159 | 186 | 141 | 161 | 188 | 205 | |
Equity & Liab. | 2,532 | 2,848 | 3,741 | 4,360 | 4,084 | 5,025 | 6,324 | 9,108 | 9,686 | 10,998 | |
Non Curr. Assets | 859 | 1,142 | 1,672 | 1,787 | 2,085 | 2,203 | 2,417 | 4,702 | 5,358 | 5,335 | |
Curr. Assets | 1,673 | 1,707 | 2,069 | 2,574 | 1,943 | 2,820 | 3,880 | 4,404 | 4,325 | 5,662 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,532 | 2,848 | 3,741 | 4,360 | 4,084 | 5,025 | 6,324 | 9,108 | 9,686 | 10,998 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 3,323 | 3,944 | 4,382 | 4,921 | 4,980 | 5,872 | 6,214 | 7,782 | 8,749 | 9,946 | |
Other Income | 76 | 71 | 89 | 72 | 53 | 104 | 171 | 196 | 129 | 236 | |
Total Income | 3,399 | 4,015 | 4,471 | 4,993 | 5,033 | 5,976 | 6,385 | 7,978 | 8,878 | 10,183 | |
Total Expenditure | -2,738 | -3,185 | -3,531 | -3,927 | -4,055 | -4,427 | -4,565 | -5,791 | -6,848 | -7,586 | |
PBIDT | 662 | 830 | 940 | 1,066 | 978 | 1,549 | 1,820 | 2,187 | 2,031 | 2,597 | |
Interest | -2 | -3 | -4 | -25 | -44 | -23 | -21 | -60 | -46 | -29 | |
Depreciation | -39 | -43 | -31 | -46 | -69 | -99 | -119 | -167 | -326 | -378 | |
Taxation | -177 | -244 | -290 | -323 | -264 | -382 | -399 | -522 | -362 | -446 | |
Exceptional Items | |||||||||||
PAT | 444 | 540 | 616 | 672 | 610 | 1,056 | 1,293 | 1,453 | 1,310 | 1,743 | |
Minority Interest | -6 | -28 | -32 | -26 | -28 | -19 | -28 | -32 | |||
Share Associate | 1 | 2 | 0 | -3 | 16 | ||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 439 | 542 | 629 | 656 | 579 | 1,030 | 1,265 | 1,433 | 1,282 | 1,727 | |
Adjusted EPS | 11 | 14 | 16 | 16 | 14 | 26 | 32 | 36 | 32 | 43 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 280 | 537 | 628 | 639 | 600 | 1,072 | 1,137 | 920 | 1,813 | |
Cash Fr. Inv. | -348 | -152 | -625 | -505 | -444 | -439 | -1,222 | -1,369 | -1,054 | |
Cash Fr. Finan. | 9 | -361 | 2 | -89 | -175 | -527 | -8 | 605 | -740 | |
Net Change | -59 | 25 | 5 | 46 | -19 | 106 | -93 | 155 | 19 | |
Cash & Cash Eqvt | 39 | 78 | 87 | 135 | 116 | 226 | 127 | 283 | 305 |
Thu, 25 Apr 2024
Credit Rating Mankind Pharma Limited has informed the Exchange about Credit Rating |
Wed, 10 Apr 2024
Updates Update on Scheme of Arrangement for Amalgamation of Shree Jee Laboratory Private Limited, JPR Labs Private Limited and Jaspack Industries Private Limited with Mankind Pharma Limited |
Wed, 03 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, kindly findenclosed herewith a copy of the certificate received from KFin Technologies Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended March 31, 2024. |
Thu, 25 Apr 2024 |
Close Within 52 Week High Zone |
High Increase in 1 Month |
High Increase in 3 Months |
High Increase in 6 Months |
CCI Bearish |